<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Embolic risk and the role of anticoagulation in atrial flutter</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Embolic risk and the role of anticoagulation in atrial flutter</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Embolic risk and the role of anticoagulation in atrial flutter</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warren J Manning, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan M Prutkin, MD, MHA, MHS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients with atrial flutter should be considered for chronic anticoagulation in a manner similar to those with atrial fibrillation (AF). This recommendation is based not only on the fact atrial flutter carries a risk for systemic embolization but also that these patients usually have episodes of AF. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'</a>.)</p><p>Our approach to anticoagulation applies to all types of atrial flutter, whether it is typical or atypical. (See  <a class="medical medical_review" href="/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE OF THROMBUS</span><span class="headingEndMark"> — </span>Many patients with atrial flutter have alternating periods of atrial fibrillation (AF) making it difficult to know the exact risk of thrombus formation (and subsequent embolization) specifically attributable to atrial flutter [<a href="#rid1">1</a>].</p><p>Atrial mechanical function is not normal in patients with atrial flutter. However, transmitral and left atrial appendage Doppler echocardiography commonly demonstrate more organized atrial and atrial appendage mechanical function with sustained atrial flutter, as opposed to AF, in which organized atrial contraction is absent. One study performed transesophageal echocardiography (TEE) immediately before and after cardioversion in 19 patients with atrial flutter and 44 patients with AF with the following findings [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to cardioversion, patients with atrial flutter had greater left atrial appendage peak ejection velocities and shear rates compared to those with AF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After cardioversion, left atrial appendage peak ejection velocities and shear rates decreased in both groups of patients, but the impaired left atrial appendage function was less pronounced in patients with atrial flutter. New or increased spontaneous echo contrast, a marker of blood stasis, occurred significantly less often in patients with atrial flutter (21 versus 50 percent for AF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Like AF, the vast majority of thrombi among patients with atrial flutter are located in the left atrial appendage. </p><p></p><p>TEE evidence of atrial thrombi has been documented in a number of reports of patients with atrial flutter not receiving chronic anticoagulation [<a href="#rid3">3-8</a>]. As with AF, the thrombi overwhelmingly involve or are exclusively within the left atrial appendage. The frequency with which this occurs may vary with the duration of the arrhythmia and other risk factors (similar to AF) as illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Two series evaluated patients with atrial flutter for a mean duration of 33 to 36 days who did not have a history of AF, rheumatic heart disease, or a prosthetic heart valve [<a href="#rid3">3,4</a>]. A left atrial thrombus was found in 1 to 1.6 percent, a right atrial thrombus in 1 percent, and left atrial spontaneous echo contrast in 11 to 13 percent [<a href="#rid3">3,4</a>]. In one of these reports, there was a close correlation between a history of thromboembolism and periods of AF during atrial flutter [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial thrombi and spontaneous echo contrast may be more common in patients with atrial flutter of longer duration. In a TEE study of 30 patients with persistent atrial flutter (duration 6.4 months), two patients (7 percent) had thrombus in the left atrial appendage, and 25 percent had spontaneous echo contrast prior to cardioversion [<a href="#rid5">5</a>]. As described below in more depth (see <a class="local">'Cardioversion'</a> below) and mentioned above, left atrial contractile function (as measured by peak atrial appendage ejection velocity) transiently <strong>declines</strong> after cardioversion in many patients and is considered a manifestation of atrial "stunning."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left atrial thrombus was present in 5 of 47 consecutive patients (11 percent) with atrial flutter for a mean duration of 28 days who did not have a history of AF or mitral stenosis [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H458946394"><span class="h1">EMBOLIC RISK</span><span class="headingEndMark"> — </span>The risk of embolization in atrial flutter is related to risk factors and the need for cardioversion or ablation. </p><p class="headingAnchor" id="H529118712"><span class="h2">Risk factors and lone atrial flutter</span><span class="headingEndMark"> — </span>Risk factors for clinical thromboembolism include valvular heart disease (eg, rheumatic valve disease, prosthetic valves), increasing age, depressed left ventricular systolic function or heart failure, hypertension, diabetes, vascular disease, and a history of thromboembolism. </p><p>Atrial flutter without an identifiable risk factor is called lone atrial flutter. It is relatively uncommon, occurring in only 3 of 181 adults with atrial flutter in a population-based study (1.7 percent) [<a href="#rid9">9</a>] and in 8 percent of children and young adults with atrial flutter in a multicenter series [<a href="#rid10">10</a>].</p><p>The embolic risk associated with lone atrial flutter was evaluated in a review of 59 mostly elderly patients with lone atrial flutter (mean age at diagnosis 70 years); 75 percent developed recurrent episodes or persistent atrial flutter [<a href="#rid11">11</a>]. At presentation, these patients did not have coronary heart disease, hyperthyroidism, heart failure, valvular heart disease, congenital heart disease, obstructive lung disease, uncontrolled hypertension, or known antecedent atrial fibrillation (AF). At the time of diagnosis, 25 were treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and six with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>; at last follow-up, 28 were treated with aspirin and 13 with warfarin.</p><p>The following observations were noted at an average follow-up of 10 years:</p><p>AF developed in 33 patients (56 percent), which was paroxysmal in 25 and permanent in eight, highlighting the rationale for managing anticoagulation in patients with atrial flutter in a manner similar to AF. </p><p class="bulletIndent1"><span class="glyph">●</span>One or more ischemic cerebrovascular events occurred in 19 patients (32 percent) at a mean age of 80 years, including six who were in AF at the time of the event. Compared to age- and sex-adjusted expected rates of thromboembolism, the thromboembolic risk was significantly increased in the patients with lone atrial flutter (hazard ratio 5.2 in patients with controlled hypertension and 2.5 in patients without a history of hypertension).</p><p></p><p>When compared with patients with lone AF, the patients with lone atrial flutter had, after adjustment for age and sex, a significantly higher rate of thromboembolism (hazard ratio 2.6). The risk was lower and no longer significant when only patients without a history of hypertension were included (hazard ratio 1.9). (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a>.)</p><p class="headingAnchor" id="H529117923"><span class="h2">Long-term flutter</span><span class="headingEndMark"> — </span>There is an increased risk for clinical thromboembolism in patients with persistent atrial flutter compared to the general population without atrial arrhythmias [<a href="#rid1">1,12-14</a>]. In a systematic review based upon limited data, the long-term embolic risk in patients with sustained atrial flutter (with varying risk factors) was estimated to be approximately 3 percent per year [<a href="#rid12">12</a>]. For comparison, the rate of thromboembolism in patients with AF &lt;1 percent per year in patients with no risk factors, with the rate increasing with increasing CHA<sub>2</sub>DS<sub>2</sub>-VASc score  (<a class="graphic graphic_table graphicRef83272" href="/d/graphic/83272.html" rel="external">table 1</a>). </p><p>One problem with interpreting these data, as mentioned previously, is that many patients with persistent atrial flutter also have episodes of AF (34 percent in the preceding report [<a href="#rid13">13</a>]) also have episodes of AF. In a review of the Medicare database, the risk of stroke was significantly increased in patients with atrial flutter (relative risk 1.41 compared to a control group). In these patients, the relative risk was 1.56 in patients who subsequently had an episode of AF (similar to the risk with AF alone), while those with isolated atrial flutter had a stroke risk not significantly different from the control population (relative risk 1.11)  (<a class="graphic graphic_figure graphicRef67382" href="/d/graphic/67382.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Cardioversion</span><span class="headingEndMark"> — </span>Although the risk of clinical thromboembolization at the time of cardioversion is increased compared to individuals not undergoing cardioversion, the absolute thromboembolism risk of cardioversion for pure atrial flutter is not known with a high degree of confidence due to the fact that many patients included in reports of atrial flutter cardioversion related events also had episodes of AF (but happened to be in atrial flutter at the time of cardioversion) [<a href="#rid3">3,13,15-17</a>]. </p><p>The studies that have attempted to evaluate the risk at the time of cardioversion studied different populations. Some included patients with a prior history of thromboembolism and were thus more likely to report high event rates, while studies in which at least some patients were anticoagulated or underwent precardioversion transesophageal echocardiography (TEE) to assess for thrombus were more likely to report low event rates [<a href="#rid3">3,12-17</a>]. </p><p>Three early studies found no embolic events in a total of 314 patients with atrial flutter (and without AF) who underwent elective cardioversion for atrial flutter without anticoagulation prior to or after cardioversion [<a href="#rid4">4,18,19</a>]. However, the overall incidence is 0.6 to 1.0 percent [<a href="#rid16">16,17</a>] with a higher risk in patients with a history of AF or underlying heart disease [<a href="#rid13">13,15</a>]. In a meta-analysis of these studies, the rate of short-term emboli ranged from 0 to 7.3 percent [<a href="#rid12">12</a>].</p><p>Embolization may be related to a transient reduction in atrial mechanical function leading to post-cardioversion thrombus formation, referred to as atrial "stunning," and is present after successful cardioversion of atrial flutter [<a href="#rid2">2,5,6,20,21</a>]. In one report, left atrial appendage peak ejection velocity fell by 26 percent within 15 minutes of cardioversion and almost 50 percent of subjects had new or more pronounced spontaneous echo contrast [<a href="#rid5">5</a>]. These changes predispose to de novo thrombus formation [<a href="#rid15">15</a>]. Similar observations have been made in patients with AF. (See  <a class="medical medical_review" href="/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Atrial stunning'</a>.)</p><p>The severity of atrial stunning appears to be somewhat less pronounced in atrial flutter than in AF, which could explain the lower embolic risk after cardioversion in atrial flutter. In a report that compared 19 patients with atrial flutter with 44 patients with AF, the left atrial appendage peak ejection velocity was significantly higher in the patients with atrial flutter at baseline (42 versus 28 cm/sec in atrial fibrillation) and after cardioversion (27 versus 15 cm/sec) [<a href="#rid2">2</a>]. In addition, new or more pronounced spontaneous echo contrast was significantly less likely in those with atrial flutter (21 versus 50 percent).</p><p class="headingAnchor" id="H458947186"><span class="h2">Radiofrequency catheter ablation</span><span class="headingEndMark"> — </span>Atrial stunning (see <a class="local">'Cardioversion'</a> above) also occurs after radiofrequency catheter ablation [<a href="#rid21">21,22</a>]. The likelihood of developing atrial stunning and its duration were assessed in a review of 15 patients with persistent atrial flutter (mean duration 17 months) and seven with paroxysmal atrial flutter who underwent radiofrequency catheter ablation [<a href="#rid21">21</a>]. Significant left atrial appendage stunning and spontaneous echo contrast on TEE were observed after ablation in 80 percent of those with persistent flutter but in none with paroxysmal atrial flutter, suggesting that, like AF, left atrial stunning in atrial flutter is related to the duration of the arrhythmia and not the mode of reversion. These changes resolved after three weeks of sustained sinus rhythm. (See  <a class="medical medical_review" href="/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'RF catheter ablation'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">PREVENTION OF EMBOLIZATION</span></p><p class="headingAnchor" id="H529118882"><span class="h2">Patients with long-term atrial flutter</span><span class="headingEndMark"> — </span>Patients with persistent or recurrent atrial flutter who also have periods of atrial flutter-fibrillation should be treated in the same manner as those with pure atrial fibrillation (AF) [<a href="#rid23">23,24</a>]. This recommendation also applies to patients with atrial flutter who have a prior history of AF. Though the optimal management of atrial flutter without any history of AF is uncertain and may be more limited  (<a class="graphic graphic_figure graphicRef67382" href="/d/graphic/67382.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>], we and others recommend that patients with pure atrial flutter be managed similar to those with AF [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'</a>.)</p><p>Anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (goal international normalized ratio [INR] between 2.0 and 3.0) has been recommended to prevent embolization in patients with atrial flutter, similar to patients with AF (eg, using CHA<sub>2</sub>DS<sub>2</sub>-VASc criteria for nonvalvular AF). Of the non-vitamin K oral anticoagulants tested for stroke prevention in AF, in the large clinical trials, only <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> enrolled patients with atrial flutter [<a href="#rid26">26</a>]. It is likely, however, that there is similar efficacy of all the non-vitamin K oral anticoagulants (eg, apixaban, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, and <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>) for atrial flutter as well as AF.</p><p class="headingAnchor" id="H8"><span class="h2">At the time of cardioversion</span><span class="headingEndMark"> — </span>We and others recommend that anticoagulation leading to, at the time of, and after cardioversion of atrial flutter be managed in a manner similar to that for AF [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p>Patients presenting with an initial episode of atrial flutter should be treated in a manner similar to those presenting with their first episode of AF, including a transthoracic echocardiogram (TTE) to evaluate for congenital heart disease, valve disease, and left ventricular systolic function.</p><p class="headingAnchor" id="H4163554268"><span class="h2">After radiofrequency catheter ablation</span><span class="headingEndMark"> — </span>Anticoagulation recommendations following catheter ablation of AF are discussed separately. (See  <a class="medical medical_review" href="/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'Anticoagulation after RF catheter ablation'</a>.)</p><p class="headingAnchor" id="H458946271"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>The 2016 European Society of Cardiology guidelines for the management of atrial fibrillation, the 2015 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on the management of adult patient with supraventricular tachycardia, and the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on the management of patients with atrial fibrillation (and its 2019 focused update) similarly recommend managing anticoagulation in patients with atrial flutter in a manner similar to those in atrial fibrillation [<a href="#rid23">23,27-31</a>], recognizing that no report has been sufficiently large to accurately define both the risk of embolization and benefit of antithrombotic therapy in a pure atrial flutter population. </p><p class="headingAnchor" id="H476578164"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H190086348"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of embolization in atrial flutter is related to clinical risk factors and underlying cardiac disease (eg, valve disease). However, the exact rates are not known, in part due to the presence of atrial fibrillation (AF) in most cohorts studied and the coexistence of AF and atrial flutter in most individuals. (See <a class="local">'Long-term flutter'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with atrial flutter, with or without AF, we recommend an anticoagulant strategy identical to that used in patients with AF (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Prevention of embolization'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87:346.</a></li><li><a class="nounderline abstract_t">Grimm RA, Stewart WJ, Arheart K, et al. Left atrial appendage "stunning" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J Am Coll Cardiol 1997; 29:582.</a></li><li><a class="nounderline abstract_t">Corrado G, Sgalambro A, Mantero A, et al. Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J 2001; 22:1042.</a></li><li><a class="nounderline abstract_t">Schmidt H, von der Recke G, Illien S, et al. Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance. J Am Coll Cardiol 2001; 38:778.</a></li><li><a class="nounderline abstract_t">Weiss R, Marcovitz P, Knight BP, et al. Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter. Am J Cardiol 1998; 82:1052.</a></li><li><a class="nounderline abstract_t">Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography. Circulation 1997; 95:962.</a></li><li><a class="nounderline abstract_t">Bikkina M, Alpert MA, Mulekar M, et al. Prevalence of intraatrial thrombus in patients with atrial flutter. Am J Cardiol 1995; 76:186.</a></li><li><a class="nounderline abstract_t">Orsinelli DA, Pearson AC. Usefulness of transesophageal echocardiography to screen for left atrial thrombus before elective cardioversion for atrial fibrillation. Am J Cardiol 1993; 72:1337.</a></li><li><a class="nounderline abstract_t">Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242.</a></li><li><a class="nounderline abstract_t">Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.</a></li><li><a class="nounderline abstract_t">Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Med 2004; 140:265.</a></li><li><a class="nounderline abstract_t">Ghali WA, Wasil BI, Brant R, et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med 2005; 118:101.</a></li><li><a class="nounderline abstract_t">Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82:580.</a></li><li><a class="nounderline abstract_t">Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997; 30:1506.</a></li><li><a class="nounderline abstract_t">Mehta D, Baruch L. Thromboembolism following cardioversion of "common" atrial flutter. Risk factors and limitations of transesophageal echocardiography. Chest 1996; 110:1001.</a></li><li><a class="nounderline abstract_t">Elhendy A, Gentile F, Khandheria BK, et al. Thromboembolic complications after electrical cardioversion in patients with atrial flutter. Am J Med 2001; 111:433.</a></li><li><a class="nounderline abstract_t">Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.</a></li><li><a class="nounderline abstract_t">Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19:851.</a></li><li><a class="nounderline abstract_t">Chalasani P, Cambre S, Silverman ME. Direct-current cardioversion for the conversion of atrial flutter. Am J Cardiol 1996; 77:658.</a></li><li><a class="nounderline abstract_t">Jordaens L, Missault L, Germonpré E, et al. Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion. Am J Cardiol 1993; 71:63.</a></li><li><a class="nounderline abstract_t">Sparks PB, Jayaprakash S, Vohra JK, et al. Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol 1998; 32:468.</a></li><li><a class="nounderline abstract_t">Welch PJ, Afridi I, Joglar JA, et al. Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. Am J Cardiol 1999; 84:420.</a></li><li><a class="nounderline abstract_t">You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.</a></li><li><a class="nounderline abstract_t">American College of Cardiology Foundation, American Heart Association, European Society of Cardiology, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013; 127:1916.</a></li><li><a class="nounderline abstract_t">Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.</a></li><li><a class="nounderline abstract_t">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</a></li></ol></div><div id="topicVersionRevision">Topic 1066 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11165976" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk of stroke in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060897" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Left atrial appendage "stunning" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11428839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale SocietàItaliana di Ecografia Cardiovascolare) multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527633" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817480" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054758" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611160" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of intraatrial thrombus in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256722" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Usefulness of transesophageal echocardiography to screen for left atrial thrombus before elective cardioversion for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127467" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence and predictors of atrial flutter in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031302" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atrial flutter in the young: a collaborative study of 380 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970149" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The natural history of lone atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15694889" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732883" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of thromboembolic events in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362409" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thromboembolism in chronic atrial flutter: is the risk underestimated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874259" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thromboembolism following cardioversion of "common" atrial flutter. Risk factors and limitations of transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11690567" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thromboembolic complications after electrical cardioversion in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225717" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610624" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Direct-current cardioversion for the conversion of atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420237" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468080" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315271" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545139" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574273" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870978" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Apixaban versus warfarin in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409259" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
